Precigen’s CEO Trading Plan Changes Stir Investor Concerns Over Governance and Insider Confidence
TipRanks (Thu, 6-Aug 2:01 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Wed, 5-Aug 7:24 AM ET)
Precigen GAAP EPS of $0.05 beats by $0.06, revenue of $54.98M beats by $27.15M
Seeking Alpha News (Tue, 4-Aug 4:11 PM ET)
PRNewswire (Tue, 4-Aug 4:01 PM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 4-Aug 10:00 AM ET)
Seeking Alpha News (Mon, 3-Aug 5:35 PM ET)
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL)
TipRanks (Mon, 3-Aug 6:20 AM ET)
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
PRNewswire (Tue, 21-Jul 8:01 AM ET)
ACCESS Newswire (Mon, 15-Jun 6:40 AM ET)
Market Chameleon (Fri, 12-Jun 6:33 AM ET)
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Precigen trades on the NASDAQ stock market under the symbol PGEN.
As of August 6, 2026, PGEN stock price climbed to $6.91 with 6,285,396 million shares trading.
PGEN has a beta of 0.96, meaning it tends to be less sensitive to market movements. PGEN has a correlation of 0.02 to the broad based SPY ETF.
PGEN has a market cap of $2.47 billion. This is considered a Mid Cap stock.
Last quarter Precigen reported $55 million in Revenue and $.05 earnings per share. This beat revenue expectation by $27 million and exceeded earnings estimates by $.06.
In the last 3 years, PGEN traded as high as $7.23 and as low as $.65.
The top ETF exchange traded funds that PGEN belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
PGEN has outperformed the market in the last year with a price return of +258.0% while the SPY ETF gained +23.6%. PGEN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +59.6% and +29.9%, respectively, while the SPY returned +6.5% and +2.8%, respectively.
PGEN support price is $6.59 and resistance is $7.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PGEN shares will trade within this expected range on the day.